JP2022513164A5 - - Google Patents

Info

Publication number
JP2022513164A5
JP2022513164A5 JP2021531011A JP2021531011A JP2022513164A5 JP 2022513164 A5 JP2022513164 A5 JP 2022513164A5 JP 2021531011 A JP2021531011 A JP 2021531011A JP 2021531011 A JP2021531011 A JP 2021531011A JP 2022513164 A5 JP2022513164 A5 JP 2022513164A5
Authority
JP
Japan
Prior art keywords
cell population
cell
peripheral blood
blood mononuclear
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064074 external-priority patent/WO2020113234A1/en
Publication of JP2022513164A publication Critical patent/JP2022513164A/ja
Publication of JP2022513164A5 publication Critical patent/JP2022513164A5/ja
Pending legal-status Critical Current

Links

JP2021531011A 2018-11-30 2019-12-02 胎盤由来同種car-t細胞およびその使用 Pending JP2022513164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862774142P 2018-11-30 2018-11-30
US62/774,142 2018-11-30
US201962878736P 2019-07-25 2019-07-25
US62/878,736 2019-07-25
PCT/US2019/064074 WO2020113234A1 (en) 2018-11-30 2019-12-02 Placenta-derived allogeneic car-t cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2022513164A JP2022513164A (ja) 2022-02-07
JP2022513164A5 true JP2022513164A5 (cg-RX-API-DMAC7.html) 2022-12-19

Family

ID=69005946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531011A Pending JP2022513164A (ja) 2018-11-30 2019-12-02 胎盤由来同種car-t細胞およびその使用

Country Status (13)

Country Link
US (1) US20220118014A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886876A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022513164A (cg-RX-API-DMAC7.html)
KR (1) KR20210111244A (cg-RX-API-DMAC7.html)
CN (1) CN113395972A (cg-RX-API-DMAC7.html)
AU (1) AU2019387571A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021010132A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120364A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021006402A (cg-RX-API-DMAC7.html)
PH (1) PH12021551246A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105217RA (cg-RX-API-DMAC7.html)
WO (1) WO2020113234A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103263B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069258A1 (en) * 2019-12-04 2022-10-12 Celularity Inc. Placenta-derived allogeneic car-t cells and uses thereof
CA3186065A1 (en) * 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Cd20結合分子及びその使用
CN122003245A (zh) * 2023-07-10 2026-05-08 普拉里生物科技有限公司 用于过继转移细胞疗法的基因工程化黏膜相关恒定t (mait)细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
CA3103505C (en) * 2006-05-11 2023-07-04 Celularity Inc. Methods for collecting and using placenta cord blood stem cells
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CN105916521A (zh) * 2013-11-15 2016-08-31 人类起源公司 包含人胎盘灌注液细胞、其亚群的组合物及其用途
SG10201808811QA (en) * 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
AU2015317316A1 (en) * 2014-09-19 2017-04-06 City Of Hope Central memory T cells for adoptive T cell therapy
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
HK1246180A1 (zh) * 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
US20160228547A1 (en) * 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
US20160237407A1 (en) * 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
NZ737556A (en) * 2015-05-26 2022-11-25 Celularity Inc Angiogenesis using stimulated placental stem cells
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CA2999070A1 (en) * 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药(上海)有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN109072194B (zh) * 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
US20200087681A1 (en) * 2016-12-21 2020-03-19 Ucl Business Plc Therapeutic cells

Similar Documents

Publication Publication Date Title
Wu et al. CD3+ CD4-CD8-(double-negative) T cells in inflammation, immune disorders and cancer
Li et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Leung Use of NK cell activity in cure by transplant
Gattinoni et al. T memory stem cells in health and disease
Mehta et al. Cord blood as a source of natural killer cells
Seliger et al. Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
US20210228632A1 (en) Compostion for use in immunotherapy
Zeng et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance
Cerwenka et al. Natural killer cell memory in infection, inflammation and cancer
Ni et al. Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Amrolia et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
Oevermann et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation
Berger et al. Adoptive transfer of virus-specific and tumor-specific T cell immunity
WO2012156958A4 (en) Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
Kroesen et al. A transplantable TH‐MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma
JP5118624B2 (ja) 新規なヒトt細胞集団
JP2016539929A5 (cg-RX-API-DMAC7.html)
Babor et al. The role of KIR genes and ligands in leukemia surveillance
Kwak et al. Insights into myeloid-derived suppressor cells in inflammatory diseases
Parisi et al. The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia
Biondi et al. Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia
Choi et al. The function of memory CD8+ T cells in immunotherapy for human diseases
Valencic et al. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation
Damele et al. Targeted therapies: friends or foes for patient’s NK cell-mediated tumor immune-surveillance?
JP2013536232A5 (cg-RX-API-DMAC7.html)